LigaChem Biosciences Full Year 2024 Earnings: Misses Expectations

LigaChem Biosciences (KOSDAQ:141080) Full Year 2024 Results

Key Financial Results

• Revenue: ₩125.9b (up 269% from FY 2023).
• Net income: ₩7.80b (up from ₩73.7b loss in FY 2023).
• Profit margin: 6.2% (up from net loss in FY 2023).
• EPS: ₩227 (up from ₩2,595 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

LigaChem Biosciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 39%.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Asia.

Performance of the market in South Korea.

The company's shares are down 2.8% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for LigaChem Biosciences that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.